Form 4 for BIIB Biogen
Accepted 2023-01-27 00:00:00 ET · period of report 2023-01-25 · accession 0001127602-23-002483 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-01-27 | 2023-01-25 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | A - Grant | $0.00 | +1,340 | 4,108 | +48% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-25 | A | A | 1,340 | $0.00 | 4,108.29 | D | — | — | (F1) Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2020. The shares will vest on February 12, 2023. |